| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 578.16 mm | 578.16 mm | 578.16 mm | 578.16 mm | 578.16 mm | 578.16 mm |
| Cash burn (monthly) | (no burn) | 120.67 k | 58.55 mm | (no burn) | (no burn) | (no burn) |
| Cash used (since last report) | n/a | 613.11 k | 297.49 mm | n/a | n/a | n/a |
| Cash remaining | n/a | 577.54 mm | 280.67 mm | n/a | n/a | n/a |
| Runway (months of cash) | n/a | 4786.3 | 4.8 | n/a | n/a | n/a |
| 13F holders | Current |
|---|---|
| Total holders | 183 |
| Opened positions | 24 |
| Closed positions | 60 |
| Increased positions | 65 |
| Reduced positions | 62 |
| 13F shares | Current |
|---|---|
| Total value | 769.09 bn |
| Total shares | 270.99 mm |
| Total puts | 37.60 k |
| Total calls | 271.40 k |
| Total put/call ratio | 0.1 |
| Largest owners | Shares | Value |
|---|---|---|
| Maravai Life Sciences Holdings 2 | 130.83 mm | $998.26 mm |
| GTCR | 20.15 mm | $109.82 bn |
| Vanguard | 11.82 mm | $64.43 bn |
| 12 West Capital Management | 11.59 mm | $63.17 bn |
| BlackRock | 9.78 mm | $53.29 bn |
| Braidwell | 8.35 mm | $45.53 bn |
| MKFCF Mackenzie Financial | 6.18 mm | $31.41 bn |
| Alyeska Investment | 5.33 mm | $29.05 bn |
| Massachusetts Financial Services | 4.66 mm | $25.42 bn |
| JPM JPMorgan Chase & Co. | 4.25 mm | $23.17 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 18 Feb 25 | Kurt Oreshack | Class A Common Stock | Payment of exercise | Dispose F | No | No | 4.1 | 2,028 | 8.31 k | 165,590 |
| 18 Feb 25 | Christine Dolan | Class A Common Stock | Payment of exercise | Dispose F | No | No | 4.1 | 1,621 | 6.65 k | 230,013 |
| 18 Feb 25 | Kevin Herde | Class A Common Stock | Payment of exercise | Dispose F | No | No | 4.1 | 2,326 | 9.54 k | 287,930 |
| 31 Jan 25 | Kurt Oreshack | Class A Common Stock | Sell | Dispose S | No | Yes | 5.03 | 25,000 | 125.75 k | 167,618 |
| 15 Jan 25 | Andrew Burch | Class A Common Stock | Payment of exercise | Dispose F | No | No | 4.56 | 54,412 | 248.12 k | 369,183 |
